Racetams / noopept

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: racetams-noopept · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

CNS-active nootropics (piracetam, aniracetam, phenylpiracetam and related; noopept is a dipeptide with similar marketing). Mechanisms are incompletely characterized; reviews describe stimulant-like and psychiatric adverse effects with unsupervised use.

Human data with psilocybin: None known: no published human data with psilocybin

Evidence types on this record

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Schifano F, Catalani V, Sharif S, et al. Benefits and harms of 'smart drugs' (nootropics) in healthy individuals. Drugs 2022;82(6):633-647. — benefits and harms of smart drugs incl. piracetam
Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994;19(2):180-222. — piracetam and structurally related nootropics

Report an error in this record →